Oral osmotic device for delivery of nystatin with hydrogel driving member

• US 5,776,493 A
• Filed: 12/22/1993
• Issued: 07/07/1998
• Est. Priority Date: 07/14/1989
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Wong, Patrick S.-L., Place, Virgil A., Barclay, Brian L., Childers, Jerry D., Wright, Jeri
• Primary Examiner(s): Bawa, Raj
• Application Number:
  US08/171,875
• Time in Patent Office: 1,658 Days
• Field of Search: 424/422, 424/435, 424/468, 424/472, 424/473, 424/474
• US Class Current: 424/468
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

An osmotic device (10) for delivering a beneficial drug, such as an anti-fungal, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a compartment (13) housing a layer of an agent (14) that is insoluble to very soluble in aqueous biological fluids, e.g., saliva, and a layer (16) of a fluid swellable, hydrophilic polymer. A passageway (17) in the wall (12) connects the agent (14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the hydrophilic polymer (16). In one embodiment the beneficial agent (14) has a different color than the hydrophilic polymer (16). The wall (12) is sufficiently translucent to permit the patient to see the amount of drug/beneficial agent (14) remaining to be delivered. Marking lines (19) may be provided on the wall (12) indicating the amount of drug/agent (14) which has been delivered and/or the amount remaining to be delivered.

Claims

1. An osmotic device for retention in the oral cavity, the device consisting essentially of:

(a) a compartment containing a hydrophilic polymer in juxtaposition with a nystatin formulation for delivering 0.05 ng to 500 mg nystatin to the oral cavity at a rate that is therapeutically effective in the treatment of oral candidiasis for a period of time of 0.5 to 4 hours;

(b) the compartment being formed by a wall sized and shaped for retention in the oral cavity for a period of 0.5 hours to 4 hours, the wall surrounding and forming the compartment for containing the hydrophilic polymer and the formulation being formed at least in part of a semipermeable material;

(c) a passageway extending through the wall, the passageway communicating the formulation with the exterior of the device; and

(d) a flavoring agent contained within the wall.

2. An osmotic device for retention in the oral cavity, the device consisting essentially of:

(a) a compartment containing a hydrophilic polymer, in juxtaposition with a nystatin formulation comprising a suspending agent and 0.05 ng to 500 mg nystatin for delivering nystatin to the oral cavity at a rate that is therapeutically effective in the treatment of oral candidiasis for a period of time of 0.5 to 4 hours;

(b) the compartment being formed by a wall sized and shaped for retention in the oral cavity for a period of 0.5 hours to 4 hours, the wall surrounding and forming the compartment for containing the hydrophilic polymer and nystatin being formed of a semipermeable material;

(c) a passageway extending through the wall, the passageway communicating the nystatin with the exterior of the device;

(d) a flavoring agent contained within the wall; and

(e) a signaling means for signaling when the dose of nystatin has been delivered from the device, said means comprising a contrast between the taste of the drug formulation and the taste of the hydrophilic polymer layer.

3. An osmotic device for the controlled delivery of nystatin to the oral cavity for treating oral candidiasis, the device comprising:

(a) a fluid permeable wall sized and shaped for retention in the oral cavity for 0.5 to 12 hours, the wall defining a compartment having first and second portions;

(b) a driving layer in the first portion of the compartment;

(c) a drug formulation in the second portion of the compartment, the drug formulation comprising 0.05 ng to 500 mg nystatin and a gelling agent, the driving layer and drug formulation juxtaposed to one another within the compartment;

(d) a passageway extending through the wall, the passageway communicating the drug formulation with the exterior of the device; and

(e) a flavoring agent contained within the wall.

4. The osmotic device of claim 3 comprising a taste indicator for signaling when the nystatin has been delivered from the device.

5. The osmotic device of claim 4, wherein the taste indicator includes the drug formulation having a first flavor and the hydrophilic polymer driving layer having a second contrasting flavor.

6. The osmotic device of claim 5, wherein both the wall and the drug formulation contain a flavoring agent.

7. The osmotic device of claim 6, wherein the flavoring agent in the wall is the same as the flavoring agent in the drug formulation.

8. The device of claim 7 wherein the nystatin is delivered at a substantially constant rate over 0.5 to 4 hour delivery period.

9. The device of claim 8, wherein the device delivers about 15 to about 30 mg of nystatin over a 0.5 to 4 hour delivery period.

10. The device of claim 3, wherein the nystatin is delivered at a rate of 7.5 mg/hour.

14. The device of claim 3 wherein the nystatin is delivered at a rate of 7.5 mg/hr.

11. An osmotic device for the controlled delivery of nystatin to the oral cavity for treating oral candidiasis, the device comprising:

(a) a fluid permeable wall sized and shaped for retention in the oral cavity for an extended delivery period defining a compartment having first and second portions;

(b) a driving layer in the first portion of the compartment;

(c) a drug formulation in the second portion of the compartment, the drug formulation comprising 0.05 ng to 500 mg nystatin and a gelling agent, the hydrophilic polymer and drug formulation juxtaposed to one another within the compartment;

(d) a passageway extending through the wall, the passageway communicating the nystatin with the exterior of the device; and

(e) a taste indicator for signaling when the dose of nystatin has been delivered from the device.

12. The device of claim 11 wherein the nystatin is delivered at a substantially constant rate over a 0.5 to 4 hour delivery period.

13. The device of claim 12, wherein the device delivers about 15 to about 30 mg of nystatin over the 0.5 to 4 hour delivery period.